Penile rehabilitation with phosphodiesterase type 5 inhibitors after nerve-sparing radical prostatectomy: are we targeting the right patients?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 24388439.
- Also identified by DOI 10.1016/j.eururo.2013.11.049.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The results reported in all trials comparing chronic versus on-demand phosphodiesterase type 5 inhibitor use after bilateral nerve-sparing radical prostatectomy may be affected by improper patient selection. Targeting the right patients is the key to optimizing the efficacy of these drugs.
Medical subject headings
- Erectile Dysfunction
- Phosphodiesterase 5 Inhibitors
- Prostatectomy